Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

The Cambridge-based biotech company has been trying to reduce operating expenses as it burns cash on its large pipeline.

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Moderna (NASDAQ:MRNA) accelerates cost cuts, trimming 2026 GAAP operating expenses by up to $500 million as COVID-19 vaccine ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

Moderna on Thursday pushed back the time frame for likely approval of a combination vaccine meant to protect against both ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...